argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Commentaires

Articles les plus consultés